Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Thall

Showing results (51-60 of 190) with videos related to

Pageof 19
Sort By:
Statistics in Medicine|May 19, 2016
Utility-based designs for randomized comparative trials with categorical outcomesThomas A Murray, Peter F Thall, Ying Yuan
Journal of the Royal Statistical Society. Series C, Applied Statistics|April 2, 2016
Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free SurvivalBrian P Hobbs, Peter F Thall, Steven H Lin
Journal of the Royal Statistical Society. Series C, Applied Statistics|March 4, 2017
Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal OutcomesPeter F Thall, Hoang Q Nguyen, Ralph G Zinner
Pharmaceutical Statistics|July 6, 2017
Bayesian nonparametric statistics: A new toolkit for discovery in cancer researchPeter F Thall, Peter Mueller, Yanxun Xu, et al.
Journal of the American Statistical Association|September 15, 2015
Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and ToxicityJuhee Lee, Peter F Thall, Yuan Ji, et al.
Biostatistics (Oxford, England)|November 11, 2015
A decision-theoretic phase I-II design for ordinal outcomes in two cyclesJuhee Lee, Peter F Thall, Yuan Ji, et al.
Clinical Trials (London, England)|January 21, 2006
Monitoring event times in early phase clinical trials: some practical issuesPeter F Thall, Leiko H Wooten, Nizar M Tannir
Biometrics|October 3, 2024
ROMI: a randomized two-stage basket trial design to optimize doses for multiple indicationsShuqi Wang, Peter F Thall, Kentaro Takeda, et al.
Statistics in Medicine|June 23, 2015
Optimization of multi-stage dynamic treatment regimes utilizing accumulated dataXuelin Huang, Sangbum Choi, Lu Wang, et al.
Journal of Biopharmaceutical Statistics|October 14, 2006
Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerationsPeter F Thall, John D Cook, Elihu H Estey
Pageof 19

Showing results (51-60 of 190) with videos related to

Sort By:
Pageof 19
Statistics in Medicine|May 19, 2016
Utility-based designs for randomized comparative trials with categorical outcomesThomas A Murray, Peter F Thall, Ying Yuan
Journal of the Royal Statistical Society. Series C, Applied Statistics|April 2, 2016
Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free SurvivalBrian P Hobbs, Peter F Thall, Steven H Lin
Journal of the Royal Statistical Society. Series C, Applied Statistics|March 4, 2017
Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal OutcomesPeter F Thall, Hoang Q Nguyen, Ralph G Zinner
Pharmaceutical Statistics|July 6, 2017
Bayesian nonparametric statistics: A new toolkit for discovery in cancer researchPeter F Thall, Peter Mueller, Yanxun Xu, et al.
Journal of the American Statistical Association|September 15, 2015
Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and ToxicityJuhee Lee, Peter F Thall, Yuan Ji, et al.
Biostatistics (Oxford, England)|November 11, 2015
A decision-theoretic phase I-II design for ordinal outcomes in two cyclesJuhee Lee, Peter F Thall, Yuan Ji, et al.
Clinical Trials (London, England)|January 21, 2006
Monitoring event times in early phase clinical trials: some practical issuesPeter F Thall, Leiko H Wooten, Nizar M Tannir
Biometrics|October 3, 2024
ROMI: a randomized two-stage basket trial design to optimize doses for multiple indicationsShuqi Wang, Peter F Thall, Kentaro Takeda, et al.
Statistics in Medicine|June 23, 2015
Optimization of multi-stage dynamic treatment regimes utilizing accumulated dataXuelin Huang, Sangbum Choi, Lu Wang, et al.
Journal of Biopharmaceutical Statistics|October 14, 2006
Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerationsPeter F Thall, John D Cook, Elihu H Estey
Pageof 19